GHP April 2017

GHP / April 2017 17 Contact: Tony Tortise Email: [email protected] Address: 1, Charterhouse Mews, London, EC1M 6BB, UK Phone: +44 (0)7387 267532 Web: Bindex ® , Osteoporosis Diagnosis is now Reliable, Fast and Easy g was a 62 year old Caucasian women who tested osteoporotic, her report giving a red result. After receiving a copy of her report she wrote confirming that the Bindex ® scan was in line with that she had previously received from a DEXA scan: “Thank you for forwarding on my report which I am grateful to receive to allow me to monitor my condition. My DEXA scan results recorded December 2015 diagnosed osteoporosis of my Lumber spine with T scores ranging from -2.7 to -3.5 and Z scores 1.4 to 2.2. The results of both necks of femur were slightly better revealing low bone mass or osteopenia rather than osteoporosis with T scores ranging from 0.4-2.4 and Z scores 0.4- 1.2. Looking at the graph given by the hospital the measurement is set at a similar level to the one you sent of my cortical bone reflecting a definite consistency between the Bindex and DEXA readings. It appears that there is variation in bone density depending on the type of bone and function with the spine and hip being the most vulnerable to osteoporosis. I am due to have my follow up DEXA scan in 2017” The World’s Largest Osteoporosis Status Screening for Women One of Europe’s top new manufacturers of medical devices, Bone Index has joined forces with Suomen Terveystalo, Finland’s largest private health care provider, and together are screening 10,000 Finnish women with Bindex ® , to provide them with accurate information about their osteoporosis status. Finland is the perfect test ground for Bindex ® . Even though the quality of health care in Finland is top-class compared to other OECD countries, only about 10% of osteoporotic patients get the treatment they need. “Bindex ® will change that for good,” says Bone Index’s CEO, Dr. Ossi Riekkinen “This is a large percentage of the Finnish population. In the US it would mean that we would screen 600,000 women in just a few months,” continues Dr. Riekkinen. Undiagnosed osteoporosis is a worldwide challenge. In the USA alone osteoporosis is responsible for two million broken bones every year, costing over 19 billion dollars. Experts forecast that by 2025, the costs will rise to 25.3 billion dollars. One of the biggest challenges is the low availability of osteoporosis diagnostics. “This is why Bindex ® is such a game-changer,” Dr. Riekkinen concludes. Suomen Terveystalo’s Senior VP Susanna Kinnari agrees: “We have over 150 clinics and the most DXA devices in Finland. We believe that with Bindex ® we will significantly improve the quality of care and provide higher accessibility to this extremely important service than ever before. This is also a great way to disseminate information on osteoporosis and its prevention and treatment.” With its portability, ease of use and cost-effectiveness, Bindex ® is set to change the way osteoporosis is diagnosed all over the world. A video showing the simplicity of Bindex ® in operation can be viewed here.